文献速递造血干细胞移植与细胞治疗血栓与止血

去纤苷在血液与骨髓移植中的应用

The use of defibrotide in blood and marrow transplantation.
PubMed 文献 · Blood Adv · 2018-01-01

本文综述去纤苷在血液与骨髓移植中的应用,重点介绍其用于造血干细胞移植后肝静脉闭塞病/窦状隙阻塞综合征(VOD/SOS)伴多器官功能障碍/衰竭(MOD/MOF)的适应证。一项3期历史对照多中心试验显示,去纤苷组移植后第+100天生存率为38.2%,高于对照组的25.0%(倾向性分析估计组间差异23%;P=0.0109)。

要点

  • 去纤苷是美国批准用于治疗HSCT后肝VOD/SOS伴肺/肾功能障碍(即MOD/MOF)的唯一疗法。
  • 欧盟批准去纤苷用于治疗HSCT后重度肝VOD/SOS。
  • 3期历史对照试验中,去纤苷组第+100天生存率38.2% vs 对照组25.0%(P=0.0109)。

核心结论

  • 去纤苷是目前唯一在美国获批用于治疗HSCT后肝VOD/SOS伴MOD/MOF的疗法,欧盟获批用于治疗HSCT后重度肝VOD/SOS。
  • 3期历史对照试验显示,去纤苷组HSCT后第+100天生存率显著高于对照组。
  • 3期预防试验发现去纤苷可降低儿童VOD/SOS发生率(非获批适应证)并减少移植物抗宿主病发生率。

研究设计与样本

  • 本文为综述,描述去纤苷的研发与临床应用,聚焦其在HSCT后VOD/SOS伴MOD/MOF中的标签内使用。
  • 纳入的3期试验为历史对照、多中心试验,纳入成人和儿童VOD/SOS伴MOD/MOF患者,去纤苷组n=102,对照组为去纤苷可及前治疗的患者n=32。
  • 另有一项3期预防试验。

主要发现

  • HSCT后VOD/SOS历史报告平均发生率为13.7%。
  • 3期历史对照试验中,去纤苷组HSCT后第+100天生存率为38.2%,对照组为25.0%(倾向性分析估计组间差异23%;P=0.0109)。
  • 最常见不良事件为低血压和腹泻;去纤苷组与历史对照组常见出血性不良事件发生率相似(分别为64%和75%)。
  • 3期预防试验中,去纤苷降低儿童VOD/SOS发生率(非获批适应证)并减少移植物抗宿主病发生率。

关键数值与推荐

  • 去纤苷是美国批准用于治疗HSCT后肝VOD/SOS伴肺/肾功能障碍(即MOD/MOF)的唯一疗法。
  • 去纤苷在欧盟获批用于治疗HSCT后重度肝VOD/SOS。
  • 3期历史对照试验中,去纤苷组第+100天生存率38.2% vs 对照组25.0%(P=0.0109)。

临床怎么用

  • 去纤苷按获批适应证用于HSCT后肝VOD/SOS伴MOD/MOF(美国)或HSCT后重度肝VOD/SOS(欧盟)。
  • 3期预防试验中去纤苷降低儿童VOD/SOS发生率属非获批适应证。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of conditioning during hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT, with a historically reported mean incidence of 13.7% post-HSCT. Typical symptoms of VOD/SOS may include hyperbilirubinemia, painful hepatomegaly, weight gain, and ascites. Defibrotide, a polydisperse mixture of predominantly single-stranded polydeoxyribonucleotides, is currently the only therapy approved to treat hepatic VOD/SOS with pulmonary/renal dysfunction (ie, multiorgan dysfunction/multiorgan failure [MOD/MOF]) following HSCT in the United States and to treat severe hepatic VOD/SOS post-HSCT in the European Union. In preclinical and human studies, defibrotide has demonstrated profibrinolytic, antithrombotic, anti-inflammatory, and angio-protective actions, thus promoting an anticoagulant phenotype of the endothelium that protects and stabilizes the function of endothelial cells. In a phase 3, historically controlled, multicenter trial in adults and children with VOD/SOS and MOD/MOF (defibrotide: n = 102; controls treated before defibrotide availability: n = 32), defibrotide resulted in significantly greater day +100 survival following HSCT (38.2%) vs controls (25.0%; propensity analysis-estimated between-group difference: 23%; P = .0109). The most common adverse events (AEs) were hypotension and diarrhea; rates of common hemorrhagic AEs were similar in the defibrotide and historical control group (64% and 75%, respectively). In a phase 3 prophylaxis trial, defibrotide was found to lower incidence of VOD/SOS in children (not an approved indication) and reduce the incidence of graft-versus-host disease. This review describes the development and clinical applications of defibrotide, focusing on its on-label use in patients with VOD/SOS and MOD/MOF after HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Richardson PG, Carreras E, Iacobelli M, et al. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018. PMID: 29945939. doi:10.1182/bloodadvances.2017008375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。